Gilead’s Livdelzi wins FDA approval, can challenge Ocaliva dominance in primary biliary cholangitis market Read more
J&J’s EGFR-mutated advanced lung cancer treatment: amivantamab-vmjw plus lazertinib gains FDA approval Read more